Abstract:Background: The study of high-throughput genomic profiles from a pharmacogenomics viewpoint has provided unprecedented insights into the oncogenic features modulating drug response. A recent study screened for the response of a thousand human cancer cell lines to a wide collection of anti-cancer drugs and illuminated the link between cellular genotypes and vulnerability. However, due to essential differences between cell lines and tumors, to date the translation into predicting drug response in tumors remains challenging. Recently, advances in deep learning have revolutionized bioinformatics and introduced new techniques to the integration of genomic data. Its application on pharmacogenomics may fill the gap between genomics and drug response and improve the prediction of drug response in tumors. Results: We proposed a deep learning model to predict drug response (DeepDR) based on mutation and expression profiles of a cancer cell or a tumor. The model contains three deep neural networks (DNNs), i) a mutation encoder pre-trained using a large pan-cancer dataset (The Cancer Genome Atlas; TCGA) to abstract core representations of high-dimension mutation data, ii) a pre-trained expression encoder, and iii) a drug response predictor network integrating the first two subnetworks. Given a pair of mutation and expression profiles, the model predicts IC50 values of 265 drugs. We trained and tested the model on a dataset of 622 cancer cell lines and achieved an overall prediction performance of mean squared error at 1.96 (log-scale IC50 values). The performance was superior in prediction error or stability than two classical methods (linear regression and support vector machine) and four analog DNN models of DeepDR, including DNNs built without TCGA pre-training, partly replaced by principal components, and built on individual types of input data. We then applied the model to predict drug response of 9059 tumors of 33 cancer types. Using per-cancer and pan-cancer settings, the model predicted both known, including EGFR inhibitors in non-small cell lung cancer and tamoxifen in ER+ breast cancer, and novel drug targets, such as vinorelbine for TTN-mutated tumors. The comprehensive analysis further revealed the molecular mechanisms underlying the resistance to a chemotherapeutic drug docetaxel in a pan-cancer setting and the anti-cancer potential of a novel agent, CX-5461, in treating gliomas and hematopoietic malignancies. Conclusions: Here we present, as far as we know, the first DNN model to translate pharmacogenomics features identified from in vitro drug screening to predict the response of tumors. The results covered both well-studied and novel mechanisms of drug resistance and drug targets. Our model and findings improve the prediction of drug response and the identification of novel therapeutic options.

Deep Learning in Pharmacogenomics: From Gene Regulation to Patient Stratification

The Next Era: Deep Learning in Pharmaceutical Research

Data Integration Using Advances in Machine Learning in Drug Discovery and Molecular Biology

The rise of deep learning in drug discovery

Deep Learning in Drug Discovery: Current Landscape and Future Prospects

Opportunities and obstacles for deep learning in biology and medicine

MMDRP: drug response prediction and biomarker discovery using multi-modal deep learning

Deep Learning in Drug Discovery and Medicine; Scratching the Surface

Deep learning in target prediction and drug repositioning: Recent advances and challenges

Applications of machine learning in drug discovery and development

A Review on the Recent Applications of Deep Learning in Predictive Drug Toxicological Studies.

Spectrum of deep learning algorithms in drug discovery

Predicting drug response of tumors from integrated genomic profiles by deep neural networks

Deep learning for computational biology

Deep learning prediction of patient response time course from early data via neural-pharmacokinetic/pharmacodynamic modeling

Application of Machine Learning in Translational Medicine: Current Status and Future Opportunities

Artificial Intelligence and Machine Learning in Pharmacological Research: Bridging the Gap Between Data and Drug Discovery

Deep learning tools for advancing drug discovery and development

Application of machine learning techniques to the analysis and prediction of drug pharmacokinetics

Deep learning for image-based diagnosis : Applications in medical imaging for drug development

Deep Learning in Drug Design—Progress, Methods, and Challenges